← All trials
NCT06615050
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 9, 2024
- Primary completion
- Oct 20, 2030
- Completion date
- Oct 20, 2030
- First posted
- Sep 26, 2024
- Last posted
- Dec 4, 2024
- Enrollment
- 572
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- IncyteLead sponsor
- National Institutes of Health (NIH)Collaborator
- National Cancer Institute (NCI)Collaborator
- Blood and Marrow Transplant Clinical Trials NetworkCollaborator
- IncyteOfficial
- National Heart, Lung, and Blood Institute (NHLBI)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.